Overview

Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy

Status:
NOT_YET_RECRUITING

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

This Phase II trial assesses Vorolanib and Sintilimab for advanced renal cell carcinoma after previous therapy failure. Participants receive the treatment until disease progression, intolerable side effects, death, or withdrawal. The primary endpoint is progression-free survival (PFS).

Phase:

PHASE2

Details

Lead Sponsor:

Hao Zeng

Treatments:

sintilimab
vorolanib